Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib Transition Study in RRMM
NCT05183139Phase 4Withdrawn
- Sponsor
- Takeda
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of ixazomib in multiple myeloma (MM), sponsored by Takeda. Planned start Jun 2022; status: withdrawn.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05183139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05183139.